Further validation in the GEO bladder cancer cohort treated with anti-PD-1 inhibitors showed that the PFS and OS of the MHC-H group was significantly longer than that of the MHC-L group (PFS, HR = 0.50, 95% CI: 0.28–0.89, log rank test P = 0.046; OS, HR = 0.43, 95% CI: 0.24–0.76, log rank test P = 0.015) (Figures 2F,G). The gene discussed is HLA-C; the disease is urinary bladder cancer.